HACL2

Summary

HACL2 (2-hydroxyacyl-CoA lyase 2, HGNC:6041) is a protein-coding gene on chromosome 19p13.12, encoding 2-hydroxyacyl-CoA lyase 2 (A1L0T0). Endoplasmic reticulum 2-OH acyl-CoA lyase involved in the cleavage (C1 removal) reaction in the fatty acid alpha-oxydation in a thiamine pyrophosphate (TPP)-dependent manner.

The protein encoded by this gene shares similarity with several thiamine pyrophosphate-binding proteins identified in bacteria, yeast, and plants. The highest degree of similarity is found with bacterial acetolactate synthases (AHAS), which are enzymes that catalyze the first step in branched-chain amino acid biosynthesis.

Source: NCBI Gene 10994 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 107 total
• Druggable target: yes
• MANE Select transcript: NM_006844

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6041
Approved symbol	HACL2
Name	2-hydroxyacyl-CoA lyase 2
Location	19p13.12
Locus type	gene with protein product
Status	Approved
Aliases	209L8, AHAS, ILV2H, MGC1269, FLJ39061, MGC19535, HACL1L, HACL2
Ensembl gene	ENSG00000105135
Ensembl biotype	protein_coding
OMIM	605770
Entrez	10994

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 28 protein_coding, 6 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000263383, ENST00000524779, ENST00000525880, ENST00000527093, ENST00000531635, ENST00000533086, ENST00000533148, ENST00000533747, ENST00000534378, ENST00000534806, ENST00000596093, ENST00000598709, ENST00000599324, ENST00000600984, ENST00000862950, ENST00000862951, ENST00000862952, ENST00000862953, ENST00000862954, ENST00000862955, ENST00000862956, ENST00000862957, ENST00000862958, ENST00000862959, ENST00000862960, ENST00000862961, ENST00000862962, ENST00000862963, ENST00000924995, ENST00000924996, ENST00000953427, ENST00000953428, ENST00000953429, ENST00000953430, ENST00000953431, ENST00000953432

RefSeq mRNA: 1 — MANE Select: NM_006844 NM_006844

CCDS: CCDS12325

Canonical transcript exons

ENST00000263383 — 16 exons

Exon	Start	End
ENSE00001302663	15114987	15115430
ENSE00001382503	15124925	15125069
ENSE00002157083	15125656	15125786
ENSE00003464667	15123375	15123576
ENSE00003465726	15119166	15119302
ENSE00003471256	15122693	15122804
ENSE00003498752	15115850	15115921
ENSE00003527741	15123116	15123243
ENSE00003552695	15122892	15123030
ENSE00003585831	15116408	15116522
ENSE00003594286	15116001	15116071
ENSE00003657778	15115566	15115671
ENSE00003674335	15119418	15119515
ENSE00003688846	15117881	15118015
ENSE00003692753	15119982	15120081
ENSE00003693971	15116152	15116321

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 97.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.0367 / max 122.0122, expressed in 1792 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179697	7.0638	1750
179698	3.6547	1520
179695	1.3155	763
179696	0.7304	476
179694	0.2723	99

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	97.64	gold quality
right atrium auricular region	UBERON:0006631	95.53	gold quality
mucosa of transverse colon	UBERON:0004991	95.43	gold quality
heart left ventricle	UBERON:0002084	95.21	gold quality
transverse colon	UBERON:0001157	95.19	gold quality
metanephros cortex	UBERON:0010533	95.12	gold quality
cardiac ventricle	UBERON:0002082	94.91	gold quality
right adrenal gland cortex	UBERON:0035827	94.61	gold quality
cardiac atrium	UBERON:0002081	94.54	gold quality
right lobe of thyroid gland	UBERON:0001119	94.37	gold quality
body of stomach	UBERON:0001161	94.25	gold quality
left adrenal gland cortex	UBERON:0035825	94.25	gold quality
right adrenal gland	UBERON:0001233	94.12	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.10	gold quality
pancreatic ductal cell	CL:0002079	94.06	gold quality
skin of leg	UBERON:0001511	94.05	gold quality
left adrenal gland	UBERON:0001234	93.99	gold quality
left lobe of thyroid gland	UBERON:0001120	93.91	gold quality
heart	UBERON:0000948	93.70	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.65	gold quality
adrenal cortex	UBERON:0001235	93.58	gold quality
right lobe of liver	UBERON:0001114	93.57	gold quality
skin of abdomen	UBERON:0001416	93.44	gold quality
thyroid gland	UBERON:0002046	93.36	gold quality
esophagus mucosa	UBERON:0002469	93.21	gold quality
nephron tubule	UBERON:0001231	93.12	gold quality
small intestine	UBERON:0002108	93.02	gold quality
lower esophagus mucosa	UBERON:0035834	92.87	gold quality
adenohypophysis	UBERON:0002196	92.83	gold quality
adrenal gland	UBERON:0002369	92.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting HACL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-3908	98.75	67.31	1160
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-3670	97.88	64.39	763
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-4329	97.68	66.26	1003
HSA-MIR-4640-5P	97.42	66.33	1543
HSA-MIR-4726-5P	97.24	65.67	1299
HSA-MIR-4653-5P	97.22	67.72	1429
HSA-MIR-873-3P	96.84	66.09	786
HSA-MIR-6508-3P	96.73	65.48	576
HSA-MIR-2861	95.24	65.47	1056

Literature-anchored findings (GeneRIF, showing 1)

• To the best of our knowledge, this is the first report of an association between single nucleotide polymorphisms (SNPs) on ILVBL and aspirin-exacerbated respiratory disease (AERD) . SNPs on ILVBL could be promising genetic markers of this condition. (PMID:29246216)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ilvbl	ENSDARG00000017126
mus_musculus	Ilvbl	ENSMUSG00000032763
rattus_norvegicus	Ilvbl	ENSRNOG00000028512
caenorhabditis_elegans		WBGENE00020831

Paralogs (1): HACL1 (ENSG00000131373)

Protein

Protein identifiers

2-hydroxyacyl-CoA lyase 2 — A1L0T0 (reviewed: A1L0T0)

Alternative names: Acetolactate synthase-like protein, IlvB-like protein

All UniProt accessions (7): A1L0T0, E9PJS0, E9PL44, E9PNL1, M0QZX5, M0R026, M0R1B5

UniProt curated annotations — full annotation on UniProt →

Function. Endoplasmic reticulum 2-OH acyl-CoA lyase involved in the cleavage (C1 removal) reaction in the fatty acid alpha-oxydation in a thiamine pyrophosphate (TPP)-dependent manner. Involved in the phytosphingosine degradation pathway.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in all tissues tested, with highest expression in heart, pancreas and placenta.

Cofactor. Binds 1 Mg(2+) ion per subunit. Binds 1 thiamine pyrophosphate per subunit.

Similarity. Belongs to the TPP enzyme family.

RefSeq proteins (1): NP_006835* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000399	TPP-bd_CS	Conserved_site
IPR011766	TPP_enzyme_TPP-bd	Domain
IPR012000	Thiamin_PyroP_enz_cen_dom	Domain
IPR012001	Thiamin_PyroP_enz_TPP-bd_dom	Domain
IPR029035	DHS-like_NAD/FAD-binding_dom	Homologous_superfamily
IPR029061	THDP-binding	Homologous_superfamily
IPR045229	TPP_enz	Family

Pfam: PF00205, PF02775, PF02776

Catalyzed reactions (Rhea), 2 shown:

• 2-hydroxyoctadecanoyl-CoA = heptadecanal + formyl-CoA (RHEA:55196)
• (2R)-hydroxyhexadecanoyl-CoA = pentadecanal + formyl-CoA (RHEA:55212)

UniProt features (8 total): binding site 3, sequence variant 2, chain 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A1L0T0-F1	94.53	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 98; 521; 547

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 154 (showing top): MORF_MTA1, GOBP_LIPID_MODIFICATION, GOBP_FATTY_ACID_CATABOLIC_PROCESS, TGACCTY_ERR1_Q2, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, MORF_PPP5C, MORF_FANCG, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, CREB_Q2_01, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, MORF_IKBKG

GO Biological Process (5): fatty acid alpha-oxidation (GO:0001561), obsolete isoleucine biosynthetic process (GO:0009097), L-valine biosynthetic process (GO:0009099), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (8): magnesium ion binding (GO:0000287), acetolactate synthase activity (GO:0003984), lyase activity (GO:0016829), thiamine pyrophosphate binding (GO:0030976), flavin adenine dinucleotide binding (GO:0050660), catalytic activity (GO:0003824), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): endoplasmic reticulum membrane (GO:0005789), acetolactate synthase complex (GO:0005948), membrane (GO:0016020), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
anion binding	2
cation binding	2
cytoplasm	2
fatty acid catabolic process	1
fatty acid oxidation	1
pyruvate family amino acid biosynthetic process	1
branched-chain amino acid biosynthetic process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
metal ion binding	1
transketolase or transaldolase activity	1
catalytic activity	1
vitamin binding	1
quaternary ammonium group binding	1
heterocyclic compound binding	1
sulfur compound binding	1
nucleotide binding	1
molecular_function	1
binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
transferase complex	1
cellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2222 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HACL2	SYDE1	Q6ZW31	538
HACL2	EPHX3	Q9H6B9	527
HACL2	LENG8	Q96PV6	480
HACL2	XYLB	O75191	435
HACL2	OR14A16	Q8NHC5	419
HACL2	MYC	P01106	391
HACL2	FH	P07954	390
HACL2	HAO2	Q9NYQ3	390
HACL2	PPCS	Q9HAB8	384
HACL2	MYRFL	Q96LU7	379
HACL2	TEKTL1	Q8IYK2	376
HACL2	PSAT1	Q9Y617	376
HACL2	H6PD	O95479	370
HACL2	IARS1	P41252	360
HACL2	SDSL	Q96GA7	357

IntAct

122 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
GBA2	ILVBL	psi-mi:“MI:0914”(association)	0.640
ILVBL	COG7	psi-mi:“MI:0914”(association)	0.640
COG7	ILVBL	psi-mi:“MI:0914”(association)	0.640
ILVBL	CEP76	psi-mi:“MI:0915”(physical association)	0.560
PICK1	ILVBL	psi-mi:“MI:0914”(association)	0.530
ILK	ILVBL	psi-mi:“MI:0914”(association)	0.530
DPEP1	ILVBL	psi-mi:“MI:0914”(association)	0.530
ILVBL	EIF2B5	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
RHOBTB3	ILVBL	psi-mi:“MI:0914”(association)	0.530
SLC6A8	ILVBL	psi-mi:“MI:0914”(association)	0.530
ZMYM4	ILVBL	psi-mi:“MI:0914”(association)	0.530
FLT4	ILVBL	psi-mi:“MI:0914”(association)	0.420
COL14A1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
TOM1	ILVBL	psi-mi:“MI:0915”(physical association)	0.370
ATXN1	ILVBL	psi-mi:“MI:0915”(physical association)	0.370
Dctn3		psi-mi:“MI:0914”(association)	0.350
SKA1	ILVBL	psi-mi:“MI:0914”(association)	0.350

BioGRID (255): CEP76 (Two-hybrid), ILVBL (Affinity Capture-MS), ILVBL (Affinity Capture-MS), ATP1B1 (Co-fractionation), CYC1 (Co-fractionation), HSD17B14 (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), ILVBL (Co-fractionation), MTCH1 (Co-fractionation)

ESM2 similar proteins: A0A7J6EK66, A0A803PDZ0, A1L0T0, A2ATU0, A2XFI3, A2Y5L9, A2YQ76, A6QQT9, A7YWE4, O22567, O61856, O78328, O82647, P20906, P28516, P33287, P39994, P51845, P51846, P51850, P51851, P66947, P9WG38, P9WG39, Q0D3D2, Q0DHF6, Q0JMH0, Q10MW3, Q38854, Q3JAD1, Q3MHH6, Q3U4I7, Q4KLP0, Q5RAP5, Q68FT3, Q6DDK5, Q6JQN1, Q6NV04, Q6YU51, Q8BU33

Diamond homologs: A1L0T0, A6QQT9, O05031, O61856, P33287, P66947, P9WG38, P9WG39, Q58077, Q6DDK5, Q6NV04, Q8BU33, B9LNE4, A0A2I2F2I5, A4IPB6, B2TJ86, O06335, O08353, O19929, O33112, O78518, O85293, P00893, P07342, P08142, P09114, P09342, P0A623, P0AEP7, P0AEP8, P0DP89, P0DP90, P14874, P17597, P27696, P27818, P27819, P27868, P36620, P37063

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 113 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SLC-mediated transmembrane transport	9	6.2×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
amino acid transport	8	23.6×	1e-06
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	5	15.9×	7e-03
cell surface receptor protein tyrosine kinase signaling pathway	6	9.8×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	12
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2493 predictions. Top by Δscore:

Variant	Effect	Δscore
19:15115427:TAAT:T	acceptor_gain	1.0000
19:15115431:C:CC	acceptor_gain	1.0000
19:15115829:C:A	donor_gain	1.0000
19:15115845:GTCAC:G	donor_loss	1.0000
19:15115846:TCAC:T	donor_loss	1.0000
19:15115847:CAC:C	donor_loss	1.0000
19:15115849:C:T	donor_loss	1.0000
19:15116145:T:TA	donor_gain	1.0000
19:15116147:CTT:C	donor_loss	1.0000
19:15116148:TTA:T	donor_loss	1.0000
19:15116149:TA:T	donor_loss	1.0000
19:15116150:A:AC	donor_gain	1.0000
19:15116150:A:AG	donor_loss	1.0000
19:15116151:C:CC	donor_gain	1.0000
19:15116227:C:CT	donor_gain	1.0000
19:15116228:C:CT	donor_gain	1.0000
19:15116318:CTCC:C	acceptor_gain	1.0000
19:15116320:CC:C	acceptor_gain	1.0000
19:15116321:CC:C	acceptor_gain	1.0000
19:15116322:C:CC	acceptor_gain	1.0000
19:15116323:T:A	acceptor_loss	1.0000
19:15116326:G:T	acceptor_gain	1.0000
19:15117875:GCTCA:G	donor_loss	1.0000
19:15117876:CTCA:C	donor_loss	1.0000
19:15117877:TCA:T	donor_loss	1.0000
19:15117878:CAC:C	donor_loss	1.0000
19:15117879:A:AC	donor_gain	1.0000
19:15117879:A:AT	donor_loss	1.0000
19:15117879:AC:A	donor_gain	1.0000
19:15117880:C:CC	donor_gain	1.0000

AlphaMissense

4041 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:15123401:G:T	A104D	0.993
19:15115635:A:G	W551R	0.990
19:15115635:A:T	W551R	0.990
19:15115883:G:C	S527R	0.989
19:15115883:G:T	S527R	0.989
19:15115885:T:G	S527R	0.989
19:15123398:G:T	A105D	0.989
19:15116037:A:C	F502L	0.986
19:15116037:A:T	F502L	0.986
19:15116039:A:G	F502L	0.986
19:15123407:A:T	V102D	0.986
19:15115300:G:C	N617K	0.985
19:15115300:G:T	N617K	0.985
19:15116053:C:T	G497E	0.984
19:15116224:C:G	D467H	0.984
19:15123393:C:G	A107P	0.984
19:15116054:C:G	G497R	0.983
19:15116054:C:T	G497R	0.983
19:15120051:A:C	F249L	0.982
19:15120051:A:T	F249L	0.982
19:15120053:A:G	F249L	0.982
19:15123399:C:G	A105P	0.982
19:15123403:A:C	F103L	0.982
19:15123403:A:T	F103L	0.982
19:15123405:A:G	F103L	0.982
19:15123419:T:A	E98V	0.982
19:15123426:G:T	R96S	0.982
19:15116053:C:A	G497V	0.980
19:15117999:G:C	F356L	0.980
19:15117999:G:T	F356L	0.980

dbSNP variants (sampled 300 via entrez): RS1000164561 (19:15117713 A>G), RS1000201223 (19:15123460 G>A), RS1000820197 (19:15123301 G>A,C), RS1001052542 (19:15124542 C>G), RS1001483880 (19:15122704 T>C,G), RS1002326123 (19:15114621 C>A,G,T), RS1002732104 (19:15120946 C>T), RS1002823944 (19:15125824 G>A), RS1003230332 (19:15127328 A>G), RS1004486215 (19:15126527 A>G), RS1004843147 (19:15121383 T>C), RS1004953511 (19:15124201 G>C,T), RS1005005869 (19:15123950 G>A), RS1005266394 (19:15118876 C>A,T), RS1005294548 (19:15124249 G>A)

Disease associations

OMIM: gene MIM:605770 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000253_12	Attention deficit hyperactivity disorder and conduct disorder	8.000000e-06
GCST003771_20	Loneliness	8.000000e-07
GCST009391_646	Metabolite levels	9.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007865	loneliness measurement
EFO:0010504	inositol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066527 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.00	Kd	1.004e+04	nM	CHEMBL5653589
5.00	ED50	1.004e+04	nM	CHEMBL5653589

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
beta-Naphthoflavone	decreases expression	2
bisphenol F	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	increases expression	1
sodium arsenite	increases expression, increases abundance	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	decreases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
triacsin C	decreases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
bisphenol S	increases expression	1
jinfukang	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	increases abundance, increases oxidation, affects cotreatment	1
Arsenic	increases abundance, increases expression	1
Cadmium	increases expression, increases abundance	1
Coumestrol	increases expression, affects cotreatment	1
Estradiol	increases expression	1
Hydrogen Peroxide	increases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Ozone	increases abundance, affects cotreatment, increases oxidation	1
Tunicamycin	increases expression	1
Valproic Acid	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651627	Binding	Binding affinity to human ILVBL incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.